UPDATE: UBS Downgrades Biogen (BIIB) to Neutral; Risk/Reward Now Balanced
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Biogen Idec (BIIB) Sells Royality, Other Rights for BENLYSTA to DRI Capital
September 10, 2012 8:39 AM EDTBiogen Idec (Nasdaq: BIIB) and DRI Capital announced that Biogen Idec has sold to a DRI Capital managed fund (DRI) its royalty and other rights relating to BENLYSTA (belimumab) to which Biogen Idec is entitled pursuant to a license agreement with Human Genome Sciences, Inc. and Glaxo Group Limited (both are companies within the GlaxoSmithKline... More
Leerink Swann Starts XenoPort (XNPT) at Outperform; Pipeline Attractive
September 6, 2012 8:18 AM EDTLeerink Swann initiates coverage on XenoPort (NASDAQ: XNPT) with an Outperform. PT $13.00.
Analyst, Irene Lau, said, "We value XNPT's later stage pipeline, Horizant and AP, at ~$6/share to which we add ~$7/share from emerging MS candidate 829, which may compete with or... More
